Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 11/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 8/20 | 0.35 |
| ▸ | BCHE | P06276 | 7/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12634799 | 0.97 | SOS1 (0.38) | SOS1ACHEGRIN1GRIN2ABCHE | |
| SCHEMBL12634767 | 0.91 | ACHE (0.36) | SOS1ACHEGRIN1GRIN2ABCHE | |
| SCHEMBL12634772 | 0.86 | ACHE (0.35) | ACHEGRIN1GRIN2ABCHETP53 | |
| SCHEMBL12426347 | 0.82 | ACHE (0.44) | SOS1ACHEGRIN1GRIN2ABCHE | |
| SCHEMBL14463345 | 0.81 | ACHE (0.46) | SOS1ACHEGRIN1GRIN2ABCHE | |
| SCHEMBL12634796 | 0.81 | CYP1A2 (0.36) | CYP1A2 | |
| SCHEMBL2200699 | 0.79 | SOS1 (0.45) | SOS1ACHEGRIN1GRIN2ABCHE | |
| SCHEMBL7506685 | 0.78 | ACHE (0.46) | SOS1ACHEGRIN1GRIN2ABCHE | |
| SCHEMBL1882382 | 0.78 | CYP1A2 (0.33) | CYP1A2 | |
| SCHEMBL1879354 | 0.76 | CYP1A2 (0.32) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947690-B2 | Insulin secretagogue and hypoglycemic agent; pyrimidine derivatives condensed with a non-aromatic ring selected from dihydrothiophene, dihydrofuran, cycloalkane moiety; 1-[2-(4-chloro-2,5-difluorophenyl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]-4-(3-hydroxypropyl)piperidin-4-ol for example | ASTELLAS PHARMA INC. (JP) | 2011-05-24 | — | — | US | disclosed |
| US-7947690-B2 | Insulin secretagogue and hypoglycemic agent; pyrimidine derivatives condensed with a non-aromatic ring selected from dihydrothiophene, dihydrofuran, cycloalkane moiety; 1-[2-(4-chloro-2,5-difluorophenyl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]-4-(3-hydroxypropyl)piperidin-4-ol for example | ASTELLAS PHARMA INC. (JP) | 2011-05-24 | — | — | US | disclosed |
| US-20080070896-A1 | Pyrimidine Derivative Condensed with a Non-Aromatic Ring | ASTELLAS PHARMA INC. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20080070896-A1 | Pyrimidine Derivative Condensed with a Non-Aromatic Ring | ASTELLAS PHARMA INC. (JP) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070896-A1 | Pyrimidine Derivative Condensed with a Non-Aromatic Ring | GPR119, IRS1, NONO | SOS1 2777/4885ACHE 3983/4885GRIN1 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.